Patents by Inventor Katsuya TSUCHIHARA

Katsuya TSUCHIHARA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210170026
    Abstract: Provided are an anticancer agent, radiosensitizer, and food composition capable of enhancing the effects of radiation therapy. The present inventors discovered that tumors shrink significantly in comparison to an untreated group and the respective monotherapy groups when treatment by burdock fruit extract containing arctigenin and radiation therapy were used in combination on mice transplanted with human pancreatic cancer cells. The anticancer agent of the present invention is an anticancer agent containing arctigenin and/or arctiin as the active ingredient, to be used in combination with radiation therapy. The arctigenin and/or arctiin may be contained as burdock, burdock fruit, burdock sprout, or forsythia, or an extract extracted from these.
    Type: Application
    Filed: July 10, 2017
    Publication date: June 10, 2021
    Applicants: KRACIE PHARMA, LTD., NATIONAL CANCER CENTER, TOKYO UNIVERSITY OF SCIENCE FOUNDATION
    Inventors: Hiroyasu ESUMI, Katsuya TSUCHIHARA, Takanori KAWASHIMA
  • Publication number: 20200207989
    Abstract: [Problem to be Solved] To provide a fluorescent probe for ALDH3A1 detection that can be used in flow cytometry adaptable to live cells. [Means of Resolution] A compound represented by general formula (I) or a salt thereof, wherein the compound or salt thereof has a retention time on an HPLC chromatogram measured under the following conditions of longer than 6.9 minutes when said compound is in aldehyde form and of 6.9 minutes or less when said compound is in carboxylic acid form.
    Type: Application
    Filed: December 6, 2017
    Publication date: July 2, 2020
    Applicant: The University of Tokyo
    Inventors: Yasuteru URANO, Tasuku UENO, Katsuya TSUCHIHARA, Atsushi YAGISHITA
  • Patent number: 9907852
    Abstract: The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: March 6, 2018
    Assignees: National University Corporation University of Toyama, Kracie Pharma, Ltd., National Cancer Center, Tokyo University of Science Foundation
    Inventors: Hiroyasu Esumi, Masafumi Ikeda, Katsuya Tsuchihara, Shigeki Chiba, Satoshi Yomoda, Takanori Kawashima, Toshiki Okubo, Yasuhiro Tezuka, Kenta Murata
  • Publication number: 20170028065
    Abstract: The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.
    Type: Application
    Filed: April 10, 2015
    Publication date: February 2, 2017
    Applicants: National University Corporation University of Toyama, Kracie Pharma, Ltd., National Cancer Center, Tokyo University of Science Foundation
    Inventors: Hiroyasu Esumi, Kouji IKEDA, Katsuya TSUCHIHARA, Shigeki Chiba, Satoshi Yomoda, Takanori Kawashima, Toshiki Okubo, Yasuhiro TEZUKA, Kenta MURATA